Valuation: MediWound Ltd.

Market Cap 204M 183M 167M 152M 287M 19.14B 296M 2.01B 802M 10.21B 764M 748M 32.24B P/E 2026 *
-6.5x
P/E 2027 * -6.48x
Enterprise Value 204M 183M 167M 152M 287M 19.14B 296M 2.01B 802M 10.21B 764M 748M 32.24B EV / Sales 2026 *
8.6x
EV / Sales 2027 * 6.4x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
1 day+6.90%
1 week+7.14%
Current month+7.14%
1 month+10.89%
3 months-0.97%
6 months-17.49%
Current year-22.81%
1 week 12.74
Extreme 12.735
14.32
1 month 11.8
Extreme 11.8
14.32
Current year 11.8
Extreme 11.8
19.7
1 year 11.8
Extreme 11.8
19.7
3 years 7.45
Extreme 7.45
24
5 years 7.1
Extreme 7.1
24.85
10 years 7.1
Extreme 7.1
57.75
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-29
Director of Finance/CFO 54 2023-05-13
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 2017-05-17
Chairman 69 2017-10-24
Director/Board Member 68 2020-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Other

Director

1,050 0.0097%
8/27/26 Sell

Chief Operating Officer

-14,958 0.1387%
6/3/26 Buy

Chairman

6,000 0.0556%
Change 5-day change 1-year change 3-year change Capi.($)
+6.90%+7.14%-18.85%+80.61% 204M
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.62%-0.67%+34.68%+77.16% 417.99B
Weighted average by Cap. -0.04%-1.96%+42.71%+88.11%

Financials

2026 *2027 *
Net sales 23.67M 21.23M 19.41M 17.71M 33.38M 2.23B 34.43M 234M 93.27M 1.19B 88.86M 86.96M 3.75B 31.81M 28.53M 26.07M 23.8M 44.84M 2.99B 46.25M 314M 125M 1.6B 119M 117M 5.04B
Net income -29.11M -26.11M -23.86M -21.78M -41.04M -2.74B -42.33M -288M -115M -1.46B -109M -107M -4.61B -31.82M -28.54M -26.08M -23.81M -44.86M -2.99B -46.27M -314M -125M -1.6B -119M -117M -5.04B
Net Debt - -
Projected Income Statement - Annual - MediWound Ltd.
Logo MediWound Ltd.
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Employees
121
Date Price Change Volume
26-11-06 US$14.25 +6.90% 111,361
26-11-05 US$13.33 -6.13% 243,052
26-11-04 US$14.20 +6.05% 329,117
26-11-03 US$13.39 -0.81% 89,861
26-11-02 US$13.50 +1.50% 120,423
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MediWound Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.25USD
Average target price
30.67USD
Spread / Average Target
+115.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MediWound Ltd.
  1. Stock Market
  2. Stocks
  3. MDWD Stock